FRE.DE : Summary for FRESENIUS SE+CO.KGAA O.N. - Yahoo Finance

U.S. Markets closed

Fresenius SE & Co. KGaA (FRE.DE)


XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
76.62-0.36 (-0.47%)
At close: 5:35PM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close76.98
Open77.14
Bid0.00 x 120700
Ask0.00 x 6100
Day's Range76.55 - 77.45
52 Week Range58.55 - 77.45
Volume1,041,003
Avg. Volume1,034,946
Market Cap42.42B
BetaN/A
PE Ratio (TTM)27.80
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Thomson Reuters StreetEventsyesterday

    Edited Transcript of FRE.DE earnings conference call or presentation 22-Feb-17 1:00pm GMT

    Full Year 2016 Fresenius SE & Co KGaA Earnings Call

  • Michelin Man Grabs a Free Lunch
    Bloomberg16 days ago

    Michelin Man Grabs a Free Lunch

    Buyers of convertible bonds are tolerating seemingly onerous terms.

  • Zacks Small Cap Researchlast month

    CTSO: Poised For Strong 2017. Fresenius Deal A Win-Win-Win

    CytoSorbents (CTSO) has had a busy last couple of months leading up to the annual JP Morgan, Biotech Showcase and Medtech Showcase conferences which were held earlier this week in San Francisco and where management took some time to talk to us.  Just prior to the company’s presentation at the Biotech Showcase they announced an expanded agreement with Fresenius and preannounced expected Q4 and FY2016 product sales. Per the January 10th preannouncement, CTSO expects Q4 product sales of ~$2.6M, implying sequential and yoy growth of approximately 21% and 74%, respectively, and marking the sixth straight quarter of record product sales.  Product sales of $2.6M is also almost 16% higher than what we had forecast ($2.2M).